|
[1]
|
LAWRENCE P B, PRICE J L. How PEGylation influences protein conformational stability[J]. Curr Opin Chem Biol, 2016, 34:88-94. |
|
[2]
|
PFISTER D, BOURGEAUX E, MORBIDELLI M. Kinetic modeling of protein PEGylation[J]. Chem Engin Sci, 2015, 137:816-827. |
|
[3]
|
YANG Z, WANG J, LU Q, et al. PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates[J]. Cancer Res, 2004, 64(18):6673-6678. |
|
[4]
|
RODR GUEZMART NEZ JA, RIVERARIVERA I, SOL RJ, et al. Enzymatic activity and thermal stability of PEG-α-chymotrypsin conjugates[J]. Biotechnol Lett, 2009, 31(6):883-887. |
|
[5]
|
姜忠义, 许松伟, 王艳强. 蛋白质和肽类分子的聚乙二醇化化学[J]. 有机化学, 2003, 23(12):1340-1347. |
|
[6]
|
ZALIPSKY S, SELTZER R, MENONRUDOLPH S. Evaluation of a new reagent for covalent attachment of polyethylene glycol to proteins[J]. Biotechnol Appl Biochem, 1992, 15(1):100-114. |
|
[7]
|
MIRON T, WILCHEK M. A simplified method for the preparation of succinimidyl carbonate polyethylene glycol for coupling to proteins[J]. Bioconjug Chem, 1993, 4(6):568-569. |
|
[8]
|
ABUCHOWSKI A, KAZO GM, JR VC, et al. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates[J]. Cancer Biochem Biophys, 1984, 7(2):175-186. |
|
[9]
|
ABUCHOWSKI A,VAN ES T,PALCZUK NC,et al. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol[J]. J Biol Chem,1977,252(11):3578-3581. |
|
[10]
|
GAIS H J, RUPPERT S. Modification and immobilization of proteins with polyethylene glycol tresylates and polysaccharide tresylates:Evidence suggesting a revision of the coupling mechanism and the structure of the polymer-polymer linkage[J]. Tetrahedron Lett, 1995, 36(22):3837-3838. |
|
[11]
|
ZALIPSKY S, LEE C. Use of functionalized poly(ethylene glycol)s for modification of polypeptides[M]//Poly(Ethylene Glycol) Chemistry. Springer US, 1992:1-15. |
|
[12]
|
WANG J, HU T, LIU Y, et al. Kinetic and stoichiometric analysis of the modification process for N-terminal PEGylation of staphylokinase[J]. Anal Biochem, 2011, 412(1):114-116. |
|
[13]
|
KINSTLER OB, BREMS DN, LAUREN SL, et al. Characterization and stability of N-terminally PEGylated rhG-CSF[J]. Pharm Res, 1996, 13(7):996-1002. |
|
[14]
|
KINSTLER OB, GABRIEL NE, FARRAR CE, et al. N-terminally chemically modified protein-compositions and method:, DE 69509628 D1[P]. 1999. |
|
[15]
|
FEE C J, DAMODARAN VB. Production of PEGylated proteins[M]//Biopharmaceutical Production Technology. 2012:199-222. |
|
[16]
|
BROCCHINI S, GODWIN A, BALAN S, et al. Disulfide bridge based PEGylation of proteins[J]. Adv Drug Deliv Rev, 2008, 60(1):3-12. |
|
[17]
|
TSUTSUMI Y, ONDA M, NAGATA S, et al. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38(LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity[J]. Proc Natl Acad Sci USA, 2000, 97(15):8548-8553. |
|
[18]
|
BANGALORE S, KUMAR S, FUSARO M, et al. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus:mixed treatment comparison analysis of 22844 patient years of follow-up from randomised trials[J]. BMJ, 2012, 345:e5170. |
|
[19]
|
PASUT G, VERONESE FM. State of the art in PEGylation:The great versatility achieved after forty years of research[J]. J Control Release, 2012, 161(2):461-472. |
|
[20]
|
MORGENSTERN J, BAUMANN P, BRUNNER C, et al. Effect of PEG molecular weight and PEGylation degree on the physical stability of PEGylated lysozyme[J]. Int J Pharm, 2017, 519(1-2):408-417. |
|
[21]
|
ROBERTS MJ, HARRIS JM. Attachment of degradable poly(ethylene glycol) to proteins has the potential to increase therapeutic efficacy[J]. J Pharm Sci, 1998, 87(11):1440-1445. |
|
[22]
|
ANDREW J. GARMAN S,BARRET KALINDJIAN. The preparation and properties of novel reversible polymer-protein conjugates 2-ω-Methoxypolyethylene (5000) glycoxymethylene-3-methylmaleyl conjugates of plasminogen activators[J]. Febs Lett, 1987, 223(2):361-365. |
|
[23]
|
田浤, 金宇灏, 陈阳建,等. 聚乙二醇氨基酸衍生物的合成及其对紫杉醇的修饰[J]. 中国药科大学学报, 2011, 42(1):78-82. |
|
[24]
|
KIZILEL S, SCAVONE A, LIU X, et al. Encapsulation of pancreatic islets within nano-thin functional polyethylene glycol coatings for enhanced insulin secretion[J]. Tissue Engin Part A, 2010, 16(7):2217. |
|
[25]
|
YOO MK, PARK IK, LIM HT, et al. Folate PEG superparamagnetic iron oxide nanoparticles for lung cancer imaging[J]. Acta Biomater, 2012, 8(8):3005-3013. |
|
[26]
|
ZHANG C, YANG XL, YUAN YH, et al. Site-specific PEGylation of therapeutic proteins via optimization of both accessible reactive amino acid residues and PEG derivatives[J]. Biodrugs, 2012, 26(4):209. 209-215. |
|
[27]
|
RYAN SIN AD M, MANTOVANI GIUSEPPE, WANG XUEXUAN, et al. Advances in PEGylation of important biotech molecules:delivery aspects[J]. Expert Opin Drug Deliv,2008,5(4):371-383. |
|
[28]
|
VUGMEYSTER Y,ENTRICAN C A,JOYCE AP,et al.Pharmacokinetic,biodistribution and biophysical profiles of TNF nanobodies conjugated to linear or branched poly (ethylene glycol)[J].Bioconjug Chem,2012,23(7):1452-1462. |
|
[29]
|
DAVIS, FF.The origin of pegnology[J]. Adv Drug Deliv Rev,2002,54(4):457-458. |
|
[30]
|
DAVIS FF, VAN EST, PALCZUK NC. Non-immunogenic polypeptides:US, US 4179337 A[P]. 1979. |
|
[31]
|
ABUCHOWSKI A,MCCOY JR,PALCZUK NC,et al. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase[J]. J Biol Chem,1977,252(11):3582-3586. |
|
[32]
|
LEE CR,MCKENZIE CA,WEBSTER KD,et al. Pegademase bovine:replacement therapy for severe combined immunodeficiency disease[J]. DICP, 1991, 25(10):1092-1095 |
|
[33]
|
"Amgen 2016 Annual Report to Stockholders"[www.amgen.com/~/media/amgen/full/www-amgen-com/downloads/investors/2016-annual-report-letter-and-10k_restrict.ashx?la=en] 2016-annual-report-letter-and-10.pdf, 2017, p. 55 |
|
[34]
|
DE GRAAF AJ, KOOIJMAN M, HENNINK WE, et al. Nonnatural amino acids for site-specific protein conjugation[J]. Bioconjug Chem, 2009, 20(7):1281. |
|
[35]
|
YANG BB, KIDO MA, MS MMS, et al. Pharmacokinetics and pharmacodynamics of pegfilgrastim in subjects with various degrees of renal function[J]. J Clin Pharmacol, 2011, 50(5):295-306. |
|
[36]
|
TURECEK PL, BOSSARD MJ, GRANINGER M,et al. BAX 855, a PEGylated rFVⅢ product with prolonged half-life. Development, functional and structural characterisation[J]. Hamostaseologie, 2012, 32(Suppl 1):S29-S38. |
|
[37]
|
WORLD HEALTH ORGANIZATION. WHO Guidelines on the Quality, Safety, and Efficacy of Biological Medicinal Products Prepared by Recombinant DNA Technology. Switzerland:WHO Press, 2013. 91-92. |
|
[38]
|
LI XL, LIU L, GAO JP, et al. Methods for identification of conjugation site on PEGylated protein[J]. Pharmaceutical Biotechnology, 2013. |
|
[39]
|
YU W, YU C, WU L, et al. PEGylated recombinant human interferon-ω as a long-acting antiviral agent:structure, antiviral activity and pharmacokinetics[J]. Antiviral Res, 2014, 108:142-147. |
|
[40]
|
JOHN B, SWAPAN C, JOHNSTON D. Characterization of poly(ethylene glycol)-modified superoxide dismutase:Comparison of capillary electrophoresis and matrix-assisted laser desorption/ionization mass spectrometry[J]. Analytical Chemistry, 1996, 68(18):3258-3264. |
|
[41]
|
李晶, 何辉, 程速远,等. 荧光胺衍生化法测定3种聚乙二醇化重组人生长激素的平均修饰率[J]. 药物分析杂志, 2014(8):1368-1373. |
点击查看大图
下载:
